Search research articles
Contact Us
Filters
Showing results (61-70 of 144) with videos related to
Page
of 15
Sort By:
Journal of Clinical and Translational Pathology
|
October 4, 2024
Androgen Drives the Expression of SARS-CoV-2 Entry Proteins in Sinonasal Tissue
Rong Rong Huang, Jenna M Giafaglione, Takao Hashimoto, et al.
BJU International
|
February 16, 2023
LUNAR: a randomized Phase 2 study of <sup>177</sup> Lutetium-PSMA Neoadjuvant to Ablative Radiotherapy for Oligorecurrent Prostate Cancer (clinical trial protocol)
Ting Martin Ma, Johannes Czernin, Carol Felix, et al.
Molecular Cancer Therapeutics
|
September 16, 2008
Pomegranate extract inhibits androgen-independent prostate cancer growth through a nuclear factor-kappaB-dependent mechanism
Matthew B Rettig, David Heber, Jiabin An, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
April 18, 2024
RECIP 1.0 Predicts Progression-Free Survival After [<sup>177</sup>Lu]Lu-PSMA Radiopharmaceutical Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer
Andrei Gafita, Loic Djaileb, Isabel Rauscher, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
January 3, 2025
Low- and High-Volume Disease in Metastatic Hormone-Sensitive Prostate Cancer: From CHAARTED to PSMA PET-An International Multicenter Retrospective Study
Lena M Unterrainer, Thomas A Hope, Wolfgang P Fendler, et al.
Biomicrofluidics
|
December 24, 2015
High efficiency vortex trapping of circulating tumor cells
Manjima Dhar, Jessica Wong, Armin Karimi, et al.
Prostate Cancer and Prostatic Diseases
|
August 17, 2021
Radiation therapy dose and androgen deprivation therapy in localized prostate cancer: a meta-regression of 5-year outcomes in phase III randomized controlled trials
Tommy Jiang, Daniela Markovic, Jay Patel, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 4, 2015
Androgen Receptor Modulation Optimized for Response (ARMOR) Phase I and II Studies: Galeterone for the Treatment of Castration-Resistant Prostate Cancer
Bruce Montgomery, Mario A Eisenberger, Matthew B Rettig, et al.
JAMA Network Open
|
January 3, 2025
PSMA-PET/CT Findings in Patients With High-Risk Biochemically Recurrent Prostate Cancer With No Metastatic Disease by Conventional Imaging
Adrien Holzgreve, Wesley R Armstrong, Kevyn J Clark, et al.
Biorxiv : the Preprint Server for Biology
|
November 1, 2024
Oncogenic Alterations, Race, and Survival in US Veterans with Metastatic Prostate Cancer Undergoing Somatic Tumor Next Generation Sequencing
Luca F Valle, Jiannong Li, Heena Desai, et al.
Page
of 15
Search research articles
Search
Showing results (61-70 of 144) with videos related to
Sort By:
Page
of 15
Journal of Clinical and Translational Pathology
|
October 4, 2024
Androgen Drives the Expression of SARS-CoV-2 Entry Proteins in Sinonasal Tissue
Rong Rong Huang, Jenna M Giafaglione, Takao Hashimoto, et al.
BJU International
|
February 16, 2023
LUNAR: a randomized Phase 2 study of <sup>177</sup> Lutetium-PSMA Neoadjuvant to Ablative Radiotherapy for Oligorecurrent Prostate Cancer (clinical trial protocol)
Ting Martin Ma, Johannes Czernin, Carol Felix, et al.
Molecular Cancer Therapeutics
|
September 16, 2008
Pomegranate extract inhibits androgen-independent prostate cancer growth through a nuclear factor-kappaB-dependent mechanism
Matthew B Rettig, David Heber, Jiabin An, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
April 18, 2024
RECIP 1.0 Predicts Progression-Free Survival After [<sup>177</sup>Lu]Lu-PSMA Radiopharmaceutical Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer
Andrei Gafita, Loic Djaileb, Isabel Rauscher, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
January 3, 2025
Low- and High-Volume Disease in Metastatic Hormone-Sensitive Prostate Cancer: From CHAARTED to PSMA PET-An International Multicenter Retrospective Study
Lena M Unterrainer, Thomas A Hope, Wolfgang P Fendler, et al.
Biomicrofluidics
|
December 24, 2015
High efficiency vortex trapping of circulating tumor cells
Manjima Dhar, Jessica Wong, Armin Karimi, et al.
Prostate Cancer and Prostatic Diseases
|
August 17, 2021
Radiation therapy dose and androgen deprivation therapy in localized prostate cancer: a meta-regression of 5-year outcomes in phase III randomized controlled trials
Tommy Jiang, Daniela Markovic, Jay Patel, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 4, 2015
Androgen Receptor Modulation Optimized for Response (ARMOR) Phase I and II Studies: Galeterone for the Treatment of Castration-Resistant Prostate Cancer
Bruce Montgomery, Mario A Eisenberger, Matthew B Rettig, et al.
JAMA Network Open
|
January 3, 2025
PSMA-PET/CT Findings in Patients With High-Risk Biochemically Recurrent Prostate Cancer With No Metastatic Disease by Conventional Imaging
Adrien Holzgreve, Wesley R Armstrong, Kevyn J Clark, et al.
Biorxiv : the Preprint Server for Biology
|
November 1, 2024
Oncogenic Alterations, Race, and Survival in US Veterans with Metastatic Prostate Cancer Undergoing Somatic Tumor Next Generation Sequencing
Luca F Valle, Jiannong Li, Heena Desai, et al.
Page
of 15